Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma
In summary, the genomic distinctions now suggest that a proportion of SMMs with progressor phenotype are akin to MM, whereas nonprogressor SMM has monoclonal gammopathy of undetermined significance-like characteristics. The results should influence further investigation in larger studies to inform future diagnostic criteria and trial designs.
Authors
- Jill Corre (ORCID: https://orcid.org/0000-0003-1580-6106)
- Kenneth Carl Anderson (ORCID: https://orcid.org/0000-0002-6418-0886)
- Joshua Rivera (ORCID: https://orcid.org/0000-0003-3816-6252)
- Mehmet Samur (ORCID: https://orcid.org/0000-0002-9978-5682)
- Bahar Dakiki (ORCID: https://orcid.org/0000-0001-9255-2475)
- Nikhil C. Munshi (ORCID: https://orcid.org/0000-0002-7344-9795)
- Giovanni Parmigiani (ORCID: https://orcid.org/0000-0002-8783-5961)
- Raphael Elie Szalat (ORCID: https://orcid.org/0000-0002-6198-3405)
- Mariateresa Fulciniti (ORCID: https://orcid.org/0000-0002-1432-9742)
- Hervé Avet‐Loiseau (ORCID: https://orcid.org/0000-0002-3050-0140)
- Anıl Aktaş Samur (ORCID: https://orcid.org/0000-0002-0183-0562)
- Adam S. Sperling (ORCID: https://orcid.org/0000-0002-9369-4413)
- Antoine Graffeuil (ORCID: https://orcid.org/0009-0002-6789-1883)
- Parth Shah (ORCID: https://orcid.org/0000-0003-2506-9525)
- Yiyang Fan (ORCID: https://orcid.org/0009-0004-3883-2213)
- Srikanth Talluri
Institutions
- Boston University (US)
- Boston Medical Center (US)
- Dartmouth–Hitchcock Medical Center (US)
- Harvard University (US)
- VA Boston Healthcare System (US)
- University Medical Center (US)
- Dana-Farber Cancer Institute (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1200/jco-25-00289
- Citations
- 1
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77